Alzheimer’s disease (AD) is the most common form of dementia and affects 44 million people worldwide. New emerging evidence from pre-clinical and clinical investigations shows that neuroinflammation is a major pathological component of AD suggesting that anti-inflammatory strategies are important in delaying the onset or slowing the progression of the disease. However, efforts to employ current anti-inflammatory agents in AD clinical trials have produced limited success. Consequently, there is a need to explore anti-inflammatory natural products, which target neuroinflammatory pathways relevant to AD pathogenesis. This review summarises important druggable molecular targets of neuroinflammation and presents classes of anti-neuroinflammatory natural products with potentials for preventing and reducing symptoms of AD.

阿尔茨海默氏病（AD）是痴呆症最常见的形式，全世界有4400万人受其影响。临床前和临床研究的新证据表明，神经炎症是AD的主要病理成分，这表明抗炎策略对于延缓疾病的发作或减慢疾病的进展至关重要。然而，在AD临床试验中采用当前抗炎药的努力取得了有限的成功。因此，需要探索抗炎天然产物，其靶向与AD发病机理有关的神经炎性途径。这篇综述总结了神经炎症的重要可药物分子靶标，并提出了具有预防和减轻AD症状潜力的抗神经炎天然产物类别。